People living with HIV need to take antiretroviral treatment for life to prevent the virus from multiplying in their body. But some people, known as "post-treatment controllers," have been able to discontinue their treatment while maintaining an undetectable viral load for several years. Starting treatment early could promote long-term control of the virus if treatment is discontinued. Scientists from the Institut Pasteur, the CEA, Inserm, Université Paris Cité and...
A study led by scientists from INRAE, the Barcelona Institute for Global Health, Inserm, and the Université Sorbonne Paris Nord, has revealed that the time at which we eat could influence our risk of developing cardiovascular disease. This study, carried out on a sample of over 100,000 people from the NutriNet-Santé cohort, followed between 2009 and 2022, suggests that eating a late first or last meal is associated with...
Attention-deficit hyperactivity disorder (ADHD) affects many children and is often accompanied by other conditions, such as metabolic disorders, asthma and dental caries. However, uncertainties remain as to the chronology of onset of such conditions, particularly when it comes to knowing which are linked with ADHD over time or, on the other hand, which increase the risk of developing ADHD symptoms. Scientists from Inserm and Université de Bordeaux at the...
Contrary to all expectations, GluD1 – a receptor considered to be excitatory – has been shown in the brain to play a major role in controlling neuron inhibition. Given that alterations in the GluD1 gene are encountered in a certain number of neurodevelopmental and psychiatric disorders, such as autism (ASD) and schizophrenia, this discovery opens up new therapeutic avenues to combat the imbalances between excitatory and inhibitory neurotransmissions associated...
Improving our knowledge of the development of the complex structures of the human head to shed new light on the congenital abnormalities that cause malformations: this is the challenge that a team of researchers from Inserm, CNRS and Sorbonne Université at the Vision Institute, Université Claude Bernard Lyon 1 and Hospices civils de Lyon is well on its way to fulfilling. Thanks to an innovative technique in which the...
Throughout 2023, and as Inserm prepares to celebrate its 60th anniversary next year, its staff has continued to promote the health of all citizens thanks to major advances across all areas of biomedical research. The work of the five scientists selected to receive this year’s prizes reflects the rich and innovative nature of Inserm research. The Inserm Grand Prize is awarded to Nadine Cerf-Bensussan, a pioneer in the exploration...
Although a high-fat, low-fiber diet is recognized as promoting cardiovascular diseases such as atherosclerosis, the mechanisms involved have not yet been fully identified. Researchers from Inserm and Université Paris Cité have studied the role of the gut microbiota in the development of atherosclerosis. Their work in mice reveals that the low fiber content of the high-fat diet leads to an imbalance in the gut microbiota, which itself causes systemic...
urrently, the treatment of heart valve diseases relies on the replacement of the dysfunctional valve with an artificial prosthesis. However, this procedure cannot be offered to all patients due to its invasive nature. In a new study, a group of researchers from laboratories shared by Inserm, ESPCI Paris, CNRS and Université Paris Cité, in close collaboration with the start-up Cardiawave spin-off of the Georges Pompidou European Hospital and the...
French, Singaporean and British researchers, led by Prof. Florent Ginhoux, head of a research team at Gustave Roussy/Inserm, have succeeded in demonstrating in a neuronal organoid the role of the brain's immune environment in its formation and development. The development of these three-dimensional structures integrating neuronal cells and the immune environment is, to date, one of the most complete in vitro models of the human brain.
Neuroscientists from Inserm, CNRS and Université de Bordeaux in France, along with Swiss researchers and neurosurgeons (EPFL/CHUV/UNIL), have designed and tested a "neuroprosthesis" to correct the gait disorders associated with Parkinson's disease. In a study published in Nature Medicine, the scientists describe the development process of the device they used to treat a Parkinson’s disease patient for the first time, enabling him to walk fluidly, confidently, and without falling.
